US Stock MarketDetailed Quotes
VCNX Vaccinex
- 4.8100
- -0.1100-2.24%
Close Aug 16 16:00 ET
- 4.8100
- 0.00000.00%
Post 20:02 ET
8.31MMarket Cap-1214P/E (TTM)
5.0000High4.5700Low80.02KVolume4.9800Open4.9200Pre Close381.45KTurnover16.71%Turnover RatioLossP/E (Static)1.73MShares52.500052wk High-1.96P/B2.30MFloat Cap4.210052wk Low--Dividend TTM478.76KShs Float2568.3000Historical High--Div YieldTTM8.74%Amplitude4.2100Historical Low4.7660Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Vaccinex Stock Forum
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
Vaccinex (VCNX) has reported positive results from its SIGNAL-AD Phase 1b/2 trial of pepinemab in early-stage Alzheimer's disease (AD). The study showed a statistically significant difference (p=0.0297) in FDG-PET signal in the medial temporal cortex after 12 months of treatment compared to placebo. Pepinemab was well-...
in Alzheimer’s Disease
Results affirm expectation of a novel mechanism of action targeting astrocyte activation to
delay progression of Alzheimer’s disease from early stage Mild Cognitive Impairment
Findings echo previous phase 2 results in Huntington’s disease based on similarities to
neuroimmune pathology in Alzheimer’s
Presentation title: Results of SIGNAL-AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with MCI or mild Alzheimer’s dementia
Presenter: Eric Siemers, MD
Featured Research Session: Glial biomarkers and Alzheimer’s disease therapeutics
Date: Wedne...
$Dow Jones Industrial Average (.DJI.US)$ rose by 0.59% to a new record high, closing at 41,211.12. In contrast, the $S&P 500 Index (.SPX.US)$ fell by 1.39%, and the $Nasdaq Composite Index (.IXIC.US)$ dropped by 2.76%. Tech stocks faced significant pressure, contributing to the mixed market performance.
Key Drivers
1. Strong Performers: $UnitedHealth (UNH.US)$, $Johnson & Johnson (JNJ.US)$, and $Cisco (CSCO.US)$ l...
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Vaccinex (Nasdaq: VCNX) will present topline data for its phase 1b/2 SIGNAL-AD study of pepinemab in Alzheimer's disease at the Alzheimer's Association International Conference on July 31, 2024. The study aims to evaluate the safety and efficacy of targeting reactive astrocytes with pepinema...
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
Vaccinex announced the completion of the last patient visit in its Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's Disease (AD). The database lock is expected in June, with key outcomes to be reported in July.
Pepinemab targets astrocyte reactivity and neuroinflammation, believed to accelerate AD progression. Key endpoints incl...
No comment yet